RxDoctor Payments Data

Gamaliel Immanuel, MD

Gastroenterology · Hempstead, NYNPI 1598855231

Payments from drug & device makers

$4,182in general payments, 2019–2025

Across 201 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Nestle Healthcare Nutrition Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$418
  • Cumberland Pharmaceuticals, Inc.$154
  • Bristol Myers Squibb$148
  • QOL Medical, LLC$146
  • plus $524 from 9 others

What the payments were for

  • Food & beverage$4,182100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,182 in reported general payments places this provider in the 60th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$132,634
Medicare patients
177
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide44$55,673
Mesalamine44$32,936
CreonLipase/Protease/Amylase14$25,475
Ursodiol63$8,698
Budesonide ErBudesonide11$7,941
Balsalazide Disodium63$6,514
Famotidine477$6,447
Lubiprostone15$3,840
Pantoprazole Sodium253$2,615
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl79$1,035
Sucralfate43$957
Rabeprazole Sodium15$468
Hydrocortisone12$215
Omeprazole20$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,701$81,14858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Hempstead

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →